CA2813911A1 - 1,4-oxazepane derivatives - Google Patents

1,4-oxazepane derivatives Download PDF

Info

Publication number
CA2813911A1
CA2813911A1 CA2813911A CA2813911A CA2813911A1 CA 2813911 A1 CA2813911 A1 CA 2813911A1 CA 2813911 A CA2813911 A CA 2813911A CA 2813911 A CA2813911 A CA 2813911A CA 2813911 A1 CA2813911 A1 CA 2813911A1
Authority
CA
Canada
Prior art keywords
group
optionally substituted
compound
alkyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2813911A
Other languages
English (en)
French (fr)
Inventor
Yuji Ishichi
Masami Yamada
Taku Kamei
Ikuo Fujimori
Yoshihisa Nakada
Tomoya Yukawa
Nobuki Sakauchi
Yusuke Ohba
Tetsuya Tsukamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44906302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2813911(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CA2813911A1 publication Critical patent/CA2813911A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02Seven-membered rings
    • C07D267/08Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/06Anti-spasmodics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2813911A 2010-10-07 2011-10-05 1,4-oxazepane derivatives Abandoned CA2813911A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2010227864 2010-10-07
JP2010-227864 2010-10-07
JP2011-175336 2011-08-10
JP2011175336 2011-08-10
PCT/JP2011/073745 WO2012046882A1 (en) 2010-10-07 2011-10-05 1,4-oxazepane derivatives

Publications (1)

Publication Number Publication Date
CA2813911A1 true CA2813911A1 (en) 2012-04-12

Family

ID=44906302

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2813911A Abandoned CA2813911A1 (en) 2010-10-07 2011-10-05 1,4-oxazepane derivatives

Country Status (26)

Country Link
US (2) US8722662B2 (https=)
EP (1) EP2625170A1 (https=)
JP (1) JP5873487B2 (https=)
KR (1) KR20130116073A (https=)
CN (1) CN103261176B (https=)
AR (1) AR083313A1 (https=)
AU (1) AU2011313150A1 (https=)
BR (1) BR112013008420A2 (https=)
CA (1) CA2813911A1 (https=)
CL (1) CL2013000927A1 (https=)
CO (1) CO6700872A2 (https=)
CR (1) CR20130158A (https=)
DO (1) DOP2013000074A (https=)
EA (1) EA201390491A1 (https=)
EC (1) ECSP13012593A (https=)
GE (1) GEP20156295B (https=)
IL (1) IL225189A0 (https=)
MX (1) MX2013003749A (https=)
NZ (1) NZ608499A (https=)
PE (1) PE20140239A1 (https=)
PH (1) PH12013500657A1 (https=)
SG (1) SG188346A1 (https=)
TW (1) TW201242956A (https=)
UY (1) UY33650A (https=)
WO (1) WO2012046882A1 (https=)
ZA (1) ZA201302112B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2630677C2 (ru) * 2011-12-21 2017-09-12 Оно Фармасьютикал Ко., Лтд. Соединения
CA2918814C (en) * 2013-07-23 2021-10-12 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma
CN105693652B (zh) * 2014-11-27 2019-01-08 常州合全药业有限公司 一种4-叔丁基-5-乙基-6-氧亚基-1,4-噁吖庚环-4,5-二甲酸基酯的合成方法
MX385021B (es) 2014-12-10 2025-03-14 Ono Pharmaceutical Co Derivado de dihidroindolizinona.
US10414723B2 (en) 2015-05-08 2019-09-17 Vertellus Holdings Llc Processes for converting carboxamides to thiocarboxamides
WO2024251807A1 (en) * 2023-06-08 2024-12-12 Cybin Irl Limited Companion animal treatments
IL325385A (en) * 2023-06-27 2026-02-01 Rycarma Therapeutics Inc Agents for the treatment of ryanodine receptor-related disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3018222A (en) 1956-08-28 1962-01-23 Ravensberg G M B H Central stimulant and appetite depressant composition
US4010166A (en) * 1974-11-25 1977-03-01 Ciba-Geigy Corporation 1,4-Oxazepines
DE3242923A1 (de) * 1982-11-20 1984-05-24 Basf Ag, 6700 Ludwigshafen 7-phenyl-7-phenoxymethyl-hexahydro-1,4-oxazepine, ihre herstellung und verwendung
EP0815134B1 (en) 1995-03-14 2002-06-05 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
JP2992677B2 (ja) 1995-06-05 1999-12-20 武田薬品工業株式会社 骨形成促進医薬組成物
JP3238414B2 (ja) 1996-02-22 2001-12-17 ニューロサーチ・アクティーゼルスカブ トロパン―誘導体、その製造方法及びその使用方法
PT929574E (pt) 1996-08-27 2005-11-30 Praecis Pharm Inc Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos
AU2001293372A1 (en) 2000-04-18 2001-10-30 Cytovia, Inc. Substituted 1,4-thiazepine and analogs and their use as activators of caspases
TW200502221A (en) * 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
GB0229743D0 (en) * 2002-12-20 2003-01-29 Arakis Ltd Novel benzoxazocines
GB0303852D0 (en) 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
WO2007049041A1 (en) 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
CN101443014A (zh) * 2006-03-10 2009-05-27 阿斯利康(瑞典)有限公司 化合物
BRPI0712429A2 (pt) 2006-05-31 2014-03-11 Hoffmann La Roche Derivados de benzazepina como inibidores de re-captação de monoamina
JP2010510962A (ja) 2006-11-24 2010-04-08 武田薬品工業株式会社 複素単環化合物およびその用途
GB0721178D0 (en) 2007-10-29 2007-12-05 Glaxo Group Ltd Chemical compounds
WO2009119528A1 (ja) 2008-03-24 2009-10-01 武田薬品工業株式会社 複素環化合物
WO2010016554A1 (ja) 2008-08-07 2010-02-11 武田薬品工業株式会社 環状アミン化合物

Also Published As

Publication number Publication date
CO6700872A2 (es) 2013-06-28
KR20130116073A (ko) 2013-10-22
MX2013003749A (es) 2013-05-09
PH12013500657A1 (en) 2013-05-06
BR112013008420A2 (pt) 2016-06-28
AR083313A1 (es) 2013-02-13
DOP2013000074A (es) 2014-07-31
CN103261176B (zh) 2015-06-03
GEP20156295B (en) 2015-06-10
ECSP13012593A (es) 2013-07-31
TW201242956A (en) 2012-11-01
WO2012046882A1 (en) 2012-04-12
JP5873487B2 (ja) 2016-03-01
EA201390491A1 (ru) 2013-11-29
UY33650A (es) 2012-04-30
IL225189A0 (en) 2013-06-27
PE20140239A1 (es) 2014-03-07
NZ608499A (en) 2015-03-27
US8722662B2 (en) 2014-05-13
CL2013000927A1 (es) 2013-09-13
SG188346A1 (en) 2013-04-30
CR20130158A (es) 2013-05-03
EP2625170A1 (en) 2013-08-14
US20120088748A1 (en) 2012-04-12
JP2013538786A (ja) 2013-10-17
ZA201302112B (en) 2013-12-23
AU2011313150A1 (en) 2013-04-18
US20130267494A1 (en) 2013-10-10
CN103261176A (zh) 2013-08-21

Similar Documents

Publication Publication Date Title
CN104981457B (zh) 杂环化合物
JP5728487B2 (ja) 三環式ヘテロ環化合物
CA2813911A1 (en) 1,4-oxazepane derivatives
US10167281B2 (en) Substituted thiazole or oxazole P2X7 receptor antagonists
US11254663B2 (en) Substituted bicyclic compounds as farnesoid X receptor modulators
US20090318412A1 (en) Tricyclic heterocyclic compound and use thereof
US20100087418A1 (en) Benzoxazepine derivatives and use thereof
CA3071825A1 (en) Heterocyclic compound
JP7612669B2 (ja) アルファ-d-ガラクトピラノシド誘導体
AU2013265376A1 (en) 5-amino[1,4]thiazines as BACE 1 inhibitors
JP2025516080A (ja) 肝疾患の治療に有用なアミドヘテロ芳香族化合物
US20100286120A1 (en) Pyridooxazepine derivative and use thereof
AU2010244551A1 (en) Isoxazole-thiazole derivatives as GABA A receptor inverse agonists for use in the treatment of cognitive disorders
US20100004249A1 (en) Bicyclic heterocyclic compound and use thereof
CN117769548A (zh) 芳香乙炔类衍生物及其制备方法和用途
CA3207069A1 (en) Compounds and methods for modulating fxr
CA3152485A1 (en) Azepane derivative
WO2025149545A1 (en) Heteroarylphenyl ether derivatives
US20260069602A1 (en) Compounds, compositions, and methods
EA052200B1 (ru) Амидогетероароматические соединения, применимые в лечении заболеваний печени
JP2002155084A (ja) 3環性複素環化合物、その製造法およびその用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161005

FZDE Discontinued

Effective date: 20181005